NCT04195867View on ClinicalTrials.gov

Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

January 8, 2019

Study Completion Date

January 8, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

Salmeterol Xinafoate

Subjects receive a daily inhaled dose of 200 μg (4 inhalations of 50 μg each).

Trial Locations (1)

08003

IMIM (Hospital del Mar Medical Research Institute), Barcelona

All Listed Sponsors
lead

Parc de Salut Mar

OTHER

NCT04195867 - Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control | Biotech Hunter | Biotech Hunter